Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for VLS-01 (buccal film DMT) in Treatment Resistant Depression. The expected timing is based on the latest available company guidance and may change.
Elumina trial. Q4 2024- Dosed first patient in Ph2 Elumina trial; topline data in Q1 2026. 12/01/25:- Continued enrollment in the Elumina Ph2 TRD trial with expanded sites in Australia and the United Kingdom; topline data guidance updated from Q1 2026 to H2 2026. 03/06/26:- Elumina Ph2 TRD topline data reiterated for H2 2026. 05/12/26:- Elumina Ph2 TRD topline results now specifically guided for Q4 2026. 07/06/26:- Last patient dosed in Ph2b Elumina (NCT06524830); topline data expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.